The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis

Lymphangioleiomyomatosis (LAM) is a destructive cystic lung disease. Mammalian target of rapamycin (mTOR) inhibitors are the primary treatment for LAM but it is unknown whether these immunosuppressing medications increase the risk for or the severity of respiratory infections in LAM patients. We sea...

Descripción completa

Detalles Bibliográficos
Autores principales: Courtwright, Andrew M., Goldberg, Hilary J., Henske, Elizabeth Petri, El-Chemaly, Souheil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2017
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484491/
https://www.ncbi.nlm.nih.gov/pubmed/28096282
http://dx.doi.org/10.1183/16000617.0004-2016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484491/
https://www.ncbi.nlm.nih.gov/pubmed/28096282
http://dx.doi.org/10.1183/16000617.0004-2016

Ejemplares similares